Posted by Michael Wonder on 21 Aug 2024
US FDA grants tentative approval of Yutrepia (treprostinil) inhalation powder for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease
19 August 2024 - Final approval of Yutrepia for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease may occur after expiration of 3 year regulatory exclusivity for Tyvaso DPI on 23 May 2025.
Liquidia Technologies announced today that the US FDA has granted tentative approval of Yutrepia (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
